Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals.
J Dermatolog Treat
; 35(1): 2351489, 2024 Dec.
Article
em En
| MEDLINE
| ID: mdl-38724042
ABSTRACT
BACKGROUND:
Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient's quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the clinician or show this area.OBJECTIVE:
to evaluate the efficacy of tralokinumab in AD patients with genital involvement.METHODS:
Adult patients with moderate/severe AD and genital involvement receiving tralokinumab have been analyzed. Primary endpoints were EASI, DLQI, PP-NRS, genital-IGA (g-IGA) and genital itching (GI) at week 16.RESULTS:
out of 48 patients with moderate/severe AD under treatment with tralokinumab, 12 patients (25%) showed a genital involvement. Seven patients reported itching in the genital area (58%), while none reported a positive history of genital infections. Median scores at T0 were EASI 17.5, PP-NRS 8 and DLQI 14. After 16 weeks of treatment, we observed a median EASI of 3, a median PP-NRS of 1 and a median DLQI of 1. Finally, concerning the genital response, after 16 weeks of treatment, we observed a statistically significant decrease in mean GI and g-IGA scores.CONCLUSION:
despite the small size of our sample, tralokinumab can be considered as a valid treatment option for AD with genital involvement.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Índice de Gravidade de Doença
/
Dermatite Atópica
/
Anticorpos Monoclonais
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article